iTRAQ技术在消化道肿瘤研究中的应用进展

doi:10.11904/j.issn.1002-3070.2020.06.013

实用肿瘤学杂志 ›› 2020, Vol. 34 ›› Issue (6): 549-553.doi: 10.11904/j.issn.1002-3070.2020.06.013

iTRAQ技术在消化道肿瘤研究中的应用进展

陈敏¹, 刘莉萍² 综述, 张玲³ 审校

1.内蒙古医科大学包头临床医学院包头市中心医院消化内科(包头 014040);
2.甘肃省金昌市中心医院综合内科;
3.内蒙古自治区包头市中心医院消化内科

收稿日期:2020-04-10 修回日期:2020-08-06 出版日期:2020-12-28 发布日期:2020-12-23
通讯作者: 张玲,E-mail:nmgbtzl2013@163.com
作者简介:陈敏,女,(1994-),硕士研究生,从事消化系统肿瘤防治的研究。
基金资助:
内蒙古医科大学科技百万工程联合项目(编号:YKD2018KJBW(LH)083)

Application progress of iTRAQ technology in gastrointestinal tumors

CHEN Min¹, LIU Liping², ZHANG Ling³

1. Department of Gastroenterology,Inner Mongolia Medical University Baotou Clinical Medical College Baotou Central Hospital,Baotou 014040,China;
2. General Internal Medicine,Jinchang Central Hospital,Gansu Province;
3. Department of Gastroenterology,Baotou Central Hospital,Inner Mongolia Autonomous Region

Received:2020-04-10 Revised:2020-08-06 Online:2020-12-28 Published:2020-12-23

摘要/Abstract

摘要： 近年来,同位素标记相对和绝对定量(Isobaric tags for relative and absolute quantification,iTRAQ)技术已成为蛋白质组学定量研究中一种强有力的工具,尤其在肿瘤相关领域备受关注,其突出优势为测定蛋白范围广泛、分析结果可靠、精确度高、重复性好等。大量文献也表明,iTRAQ技术在消化道肿瘤,如食管癌、胃癌、肝癌等肿瘤标志物筛查研究、肿瘤发生发展机制研究以及肿瘤治疗预后探索等方面得到广泛应用。在大规模定量生物学时代,iTRAQ技术在分子水平上深入了解消化道肿瘤的相关机制研究中越来越不可或缺。因此本文对iTRAQ技术在消化道肿瘤中的研究进展进行简要综述。

关键词: iTRAQ, 消化道肿瘤, 蛋白质组学

Abstract: In recent years,the isotope-labeled relative and absolute quantification(Isobaric tags for relative and absolute quantification,iTRAQ)technology has become a powerful tool for the quantitative research of proteomics,especially in tumor-related fields.The advantages are a wide range of protein determination,reliable analytical results,high accuracy and good repeatability.A large number of literatures have also shown that iTRAQ technology has been widely used in gastrointestinal tumors,such as esophageal cancer,gastric cancer,liver cancer and other tumor marker screening research,the mechanism of tumor development,and the exploration of tumor treatment and prognosis.In the era of large-scale quantitative biology,iTRAQ technology is increasingly indispensable in the molecular level of in-depth understanding of the relevant mechanisms of digestive tract tumors.Therefore,this article briefly reviews the research progress of iTRAQ technology in gastrointestinal tumors.

Key words: iTRAQ, Gastrointestinal tumors, Proteomics

中图分类号:

R735

陈敏, 刘莉萍, 张玲. iTRAQ技术在消化道肿瘤研究中的应用进展[J]. 实用肿瘤学杂志, 2020, 34(6): 549-553.

CHEN Min, LIU Liping, ZHANG Ling. Application progress of iTRAQ technology in gastrointestinal tumors[J]. Journal of Practical Oncology, 2020, 34(6): 549-553.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.06.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I6/549

参考文献

1 Liang S,Xu Z,Xu X,et al.Quantitative proteomics for cancer biomarker discovery[J].Comb Chem High Throughput Screen,2012,15(3):221-231.
2 Reichenbach ZW,Murray MG,Saxena R,et al.Clinical and translational advancesin esophageal squamous cell carcinoma[J].Adv Cancer Res,2019,144:95-135.
3 Kumagai K,Rouvelas I,Tsai JA,et al.Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer:a direct and adjusted indirect comparison meta-analysis[J].Surg Oncol,2015,41(3):282-294.
4 Wang F,Liu S,Liu J,et al.SP promotes cell proliferation in esophageal squamous cell carcinoma through the NK1R/Hes1 axis[J].Biochem Biophys Res Commun,2019,514(4):1210-1216.
5 Ma XL,Yao H,Wang X,et al.ILK predicts the efficacy of chemoradiotherapy and the prognosis of patients with esophageal squamous cell carcinoma[J].Oncol Lett,2019,18(4):4114-4125.
6 Fernández-Coto DL,Gil J,Hernández A,et al.Quantitative proteomics reveals proteins involved in the progression from non-cancerous lesions to gastric cancer[J].Proteomics,2018,186:15-27.
7 Jiang Z,Sun X,Zhang Q,et al.Identification of candidate biomarkers that involved in the epigenetic transcriptional regulation for detection gastric cancer by iTRAQ based quantitative proteomic analysis[J].Clin Chim Acta,2017,471:29-37.
8 Yang Y,Toy W,Chong LY,et al.Discovery of SLC3A2 cell membrane protein as a potential gastric cancer biomarker:implications in molecular imaging[J].Proteome Res,2012,11(12):5736-5747.
9 Li BP,Mao YT,Wang Z,et al.CLIC1 promotes the progression of gastric cancer by regulating the MAPK/AKT pathways[J].Cell Physiol Biochem,2018,46(3):907-924.
10 Zhang X,Zhu Y,Duan W,et al.Allicin induces apoptosis of the MGC-803 humangastric carcinoma cell line through the p38 mitogen-activated proteinkinase/caspase-3 signaling pathway[J].Mol Med Rep,2015,11(4):2755-2760.
11 王浩冉,潘元明,张玲.大蒜素对胃癌细胞化疗增敏机制研究[J].世界华人消化杂志,2019,27(20):1248-1255.
12 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
13 Cheng J,Wu LM,Deng XS,et al.MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway[J].Hepatobiliary Pancreat Dis Int,2018,17(4):336-344.
14 Lin Q,Peng S,Yang Y.Inhibition of CD9 expression reduces the metastatic capacity of human hepatocellular carcinoma cell line MHCC97-H[J].Int J Oncol,2018,53(1):266-274.
15 Razumilava N,Gores GJ.Cholangiocarcinoma[J].Lancet,2014,383:2168-2179.
16 Eckel F,Schmid RM.Chemotherapy in advanced biliary tract carcinoma:a pooled analysis of clinical trials[J].Br J Cancer,2007,96(6):896-902.
17 Tang Z,Yang Y,Zhao Z,et al.The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma:a systematic review and meta-analysis[J].Medicine(Baltimore),2018,97(34):e11999.
18 Marin JJG,Lozano E,Briz O,et al.Molecular bases of chemoresistance in cholangiocarcinoma[J].Curr Drug Targets,2017,18(8):889-900.
19 Ren H,Luo M,Chen J,et al.Identification of TPD52 and DNAJB1 as two novel bile biomarkers for cholangiocarcinoma by iTRAQ based quantitative proteomics analysis[J].Oncol Rep,2019,42(6):2622-2634.
20 Tang Z,Yang Y,Zhang J,et al.Quantitative proteomic analysis and evaluation of the potential prognostic biomarkers in cholangiocarcinoma[J].J Cancer,2019,10(17):3985-3999.
21 Siegel RL,Miller KD,Jemal A.Cancer statistics[J].CA Cancer J Clin,2019,69:7-34.
22 Liu XH,Zheng WM,Wang WS,et al.A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline[J].Brit J Cancer,2017,117(12):1846-1854.
23 Li H,Mao Y,Xiong Y,et al.Comprehensive proteome analysis of peripheral blood mononuclear cells(PBMCs)to identify candidate biomarkers of pancreatic cancer[J].Cancer Genomics Proteomics,2019,16(1):81-89.
24 李珊,赵春波,乔文波.术中放疗在胰腺癌中的应用进展[J].实用肿瘤学杂志,2019,33(3):280-283.
25 Lei S,He Z,Chen T,et al.Long noncoding RNA 00976 promotes pancreatic cancer progression through OTUD7B by sponging miR-137 involving EGFR/MAPK pathway[J].J Exp Clin Cancer Res,2019,38(1):470.
26 Bray F,Feday J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
27 方琳,刘超,张纯慧,等.转移性结直肠癌维持治疗的研究现状与治疗策略[J].实用肿瘤学杂志,2019,33(2):173-178.
28 Peng F,Huang Y,Li MY,et al.Dissecting characteristics and dynamics of differentially expressed proteins during multistage carcinogenesis of human colorectal cancer[J].World J Gastroenterol,2016,22(18):4515-4528.
29 Chen H,Xu L,Yin L,et al.iTRAQ-based proteomic analysis of dioscin on human HCT-116 colon cancer cells[J].Proteomics,2014,14(1):51-73.

[1]	孙晓凯, 刘付东, 梁季, 郑春早, 周金意. 江苏省盐城市2008—2018年消化道肿瘤死亡情况及其变化趋势分析[J]. 实用肿瘤学杂志, 2020, 34(6): 495-499.
[2]	王浩冉, 张玲. 大蒜素抑制消化道肿瘤细胞增殖作用的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 254-257.
[3]	吕福莲, 高翔综述, 金艾顺审校. 肿瘤干细胞潜在标志物DCLK1在消化道恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2015, 29(5): 458-461.
[4]	姚淞元,吴永梅. TAP检测在消化道肿瘤诊断和预后判断中的意义[J]. 实用肿瘤学杂志, 2015, 29(2): 122-126.
[5]	牛丽婷, 曹露综述, 赵英会, 王学春审校. 胃癌蛋白质组学的研究进展[J]. 实用肿瘤学杂志, 2013, 27(4): 355-358.
[6]	胡维博, 胡婷婷, 史健. 蛋白质组学及其在恶性肿瘤患者血浆标记物分析中的应用[J]. 实用肿瘤学杂志, 2011, 25(1): 96-100.
[7]	赵健, 徐维, 王远东, 郭爱林, 薛兴阳, 李洪胜, 韩国栋, 傅文凡. 应用蛋白芯片技术筛选肺腺癌化疗敏感血清蛋白标志物[J]. 实用肿瘤学杂志, 2010, 24(1): 20-23.
[8]	曹春晓综述, 王玉华审校. PPARγ及罗格列酮与消化系统肿瘤[J]. 实用肿瘤学杂志, 2009, 23(6): 579-581.
[9]	林朝春;叶珠赛;孙秀琴. 消化道肿瘤抑郁患者对化疗不良反应的影响与护理对策[J]. 实用肿瘤学杂志, 2008, 22(05): 468-469.
[10]	刘池波. 蛋白质组技术在胃癌相关标志物筛查中的应用[J]. 实用肿瘤学杂志, 2008, 22(03): 204-207.
[11]	黄彩萍;林朝春;叶珠赛. 奥沙利铂治疗消化道肿瘤的临床观察与护理[J]. 实用肿瘤学杂志, 2008, 22(01): 55-56.
[12]	方志坚;李德津. 以贫血为首发症状消化道肿瘤94例临床分析[J]. 实用肿瘤学杂志, 2002, 16(02): 133-134.
[13]	刘德华;华阳;李森;罗娅红. 62例消化道肿瘤的肝转移瘤的介入治疗[J]. 实用肿瘤学杂志, 2001, 15(03): 232-233.

iTRAQ技术在消化道肿瘤研究中的应用进展

Application progress of iTRAQ technology in gastrointestinal tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

编辑推荐

Metrics

本文评价